Hilser, Thomas and Casuscelli, Jozefina and Aydogdu, Can and Zschaebitz, Stefanie and Schnabel, Marco Julius and Rinderknecht, Emily and Mattigk, Angelika and Schostak, Martin and Volk, Anna-Lisa and Ivanyi, Philipp and Wiegmann, Jonas and Darr, Christopher and Flegar, Luka and Mandal, Subhajit and Schlack, Katrin and Seidl, Daniel and Handke, Analena and Klee, Melanie and Nestler, Tim and Rehlinghaus, Marc and Hijazi, Sameh and Heidenreich, Axel and Gruenwald, Viktor and Paffenholz, Pia (2025) Real-world Evidence from a Retrospective Multicentre Analysis on First-line Therapy for Metastatic Papillary Renal Cell Carcinoma. A GUARDIANS Project. EUROPEAN UROLOGY OPEN SCIENCE, 78. pp. 59-67. ISSN 2666-1691, 2666-1683
Full text not available from this repository. (Request a copy)Abstract
Background and objective: Papillary renal cell carcinoma (pRCC) is a rare disease. The optimal treatment of metastatic pRCC is still unclear. We evaluated real-world treatment outcomes of first-line treatment in this cohort in Germany. Methods: Patients with advanced or metastatic pRCC were eligible. Adverse events (AEs) were reported according to Common Terminology Criteria for Adverse Events version 5.0. The overall response rate was accessed according to the local standard. Progression-free survival (PFS) was calculated from the start of treatment to progression or death. Descriptive statistics and Kaplan-Meier plots were utilised, where appropriate. Key findings and limitations: In total, 121 suitable patients (77% male) with a median age of 63 yr (quartil 78%. Eastern Cooperative Oncology Group performance status 0-1 was reported in 74%. Lymphatic (68 es 55, 70) were included. Prior nephrectomy was performed in %) and pulmonary (42%) metastases were most common. Of the patients, 59% recei therapies (ICI-ICI: 2 received TKI monothe was 33.3 mo (interqua fidence interval [CI] : 3 for ICI-TKI combinat ved 0%, the patients, 70% a AEs of any cause le Conclusions and clinical io nd dt first-line immune checkpoint inhibitor (ICI) combination tyrosine kinase inhibitor [TKI]-ICI: 39%), and 41% of patients rapy, predominantly sunitinib. The median follow-up time rtile range 14.8-46.7). The median PFS was 5.4 mo (95% con-.2-7.6) for ICI-ICI combinations, 16.9 mo (95% CI: 7.2-26.6) ns, and 8.8 mo (95% CI: 7.0-10.7) for TKI monotherapy. Of all 35% experienced all-grade and grade 3-5 AEs, respectively. o discontinuation in 33% of patients. pRCC patients. Our da patients with pRCC. The major limitations were the retrospective data capture and short follow-up of our study. Additional analyses to tailor treatment strategies in patients with metas tatic pRCC are warranted. Patient summary: In th patients with metastat tor (TKI)-based therap of immune checkpoint pRCC. However, furthe metastatic pRCC. (c) 2025 The Author(s). Urology. This is an open implications: TKI-based therapies are applied frequently in ta support the use of ICI plus TKI as a first-line standard for is report, we looked at the outcome of first-line treatment of ic papillary renal cell cancer (pRCC). Tyrosine kinase inhibi-ies are applied frequently in pRCC. Our data support the use inhibitor plus TKI as a first-line standard for patients with r studies are needed to optimise treatment in patients with Published by Elsevier B.V. on behalf of European Association of access article under the CC BY license (http://creativecommons. org/licenses/by/4.0/).
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | OPEN-LABEL; PLUS AXITINIB; PHASE-II; SUNITINIB; CANCER; Papillary renal cell cancer; Immune checkpoint inhibitor; Tyrosine kinase inhibitor; First-line treatment |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 Mar 2026 07:00 |
| Last Modified: | 31 Mar 2026 07:00 |
| URI: | https://pred.uni-regensburg.de/id/eprint/67883 |
Actions (login required)
 |
View Item |
